What question did this study set out to answer?

To investigate the role of YAP in glioblastoma and its relationship with chemoresistance and clinical outcomes.

The Role of YAP in Overcoming Chemoresistance in Glioblastoma Treatment

View Full Paper

Ask AI

Bookmark

Authors

Uncovers YAP's involvement in chemoresistance in glioblastoma, suggesting implications for new therapies.

To investigate the role of YAP in glioblastoma and its relationship with chemoresistance and clinical outcomes.
Utilized in vitro and in vivo models to study YAP's role in glioblastoma.
Analyzed YAP expression levels in chemotherapy-sensitive and TMZ-resistant GBM strains.
Conducted YAP knockdown experiments to assess effects on malignant phenotype and tumor growth.
Evaluated the efficacy of the YAP inhibitor verteporfin to enhance susceptibility to temozolomide.
YAP upregulation in GBM correlates with poor clinical outcomes and increased drug resistance.
YAP is associated with a malignant phenotype, enhancing cell proliferation and tumor growth.
Inhibition of YAP leads to reduced tumor growth and malignancy in GBM cell lines.
Verteporfin treatment improves TMZ sensitivity in both sensitive and resistant GBM models.

Cao et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark